Dr. Peter McCullough

Whereas young, robust college kids and kids in K through 12, if they were healthy, they largely breezed right through it. So we should have actually had a differential approach to the viral infection based on risk. And the same thing is true with the vaccines. Vaccines are interesting. They're just the opposite of the illness.

Whereas young, robust college kids and kids in K through 12, if they were healthy, they largely breezed right through it. So we should have actually had a differential approach to the viral infection based on risk. And the same thing is true with the vaccines. Vaccines are interesting. They're just the opposite of the illness.

While the illness strikes severe disease in the elderly and frail, the vaccines seem to disproportionately hit young and healthy people with serious side effects like myocarditis.

While the illness strikes severe disease in the elderly and frail, the vaccines seem to disproportionately hit young and healthy people with serious side effects like myocarditis.

I was working through something. I believe you wrote this large encyclical on the spike protein and what can be done about it that the TWC is going to be hopefully pushing out pretty soon because it really is quite sweeping in its direction. And it's information. There's a lot there for people. And I think it's accessible for people the way it's written. What have we learned?

I was working through something. I believe you wrote this large encyclical on the spike protein and what can be done about it that the TWC is going to be hopefully pushing out pretty soon because it really is quite sweeping in its direction. And it's information. There's a lot there for people. And I think it's accessible for people the way it's written. What have we learned?

I have to show you my model. I have a spike protein model. So this is the virus. Let me see if I can bring it in here. Here we go. This is the virus.

I have to show you my model. I have a spike protein model. So this is the virus. Let me see if I can bring it in here. Here we go. This is the virus.

Towards your tie. There you go.

Towards your tie. There you go.

It's so hard on camera. Okay, so this is a model of the virus, and on the surface are these little spikes. That's called the spike protein. That's where all the damage is done from the virus. The ball itself, the nucleocapsid, is benign, and humans get, like, four different types of these coronaviruses without the dangerous spike protein. This was engineered in the Wuhan Institute of Virology.

It's so hard on camera. Okay, so this is a model of the virus, and on the surface are these little spikes. That's called the spike protein. That's where all the damage is done from the virus. The ball itself, the nucleocapsid, is benign, and humans get, like, four different types of these coronaviruses without the dangerous spike protein. This was engineered in the Wuhan Institute of Virology.

The spike protein was, and now even the CIA is out this week coming to their conclusion. The spike protein has two segments, the outer S1 segment and the inner S2 segment. And what you need to know is the spike protein is retained in the body after the infection,

The spike protein was, and now even the CIA is out this week coming to their conclusion. The spike protein has two segments, the outer S1 segment and the inner S2 segment. And what you need to know is the spike protein is retained in the body after the infection,

And then it's loaded into the body with genetic production of the spike protein from the Pfizer and Moderna, as well as Janssen vaccines. The Novavax vaccine is a set amount of the spike protein given to the body. So the Novavax vaccine is very different than the others. So you mentioned about differences in risks in the vaccine.

And then it's loaded into the body with genetic production of the spike protein from the Pfizer and Moderna, as well as Janssen vaccines. The Novavax vaccine is a set amount of the spike protein given to the body. So the Novavax vaccine is very different than the others. So you mentioned about differences in risks in the vaccine.

That's another aspect of the vaccine campaign that our public health officials have really disappointed Americans.

That's another aspect of the vaccine campaign that our public health officials have really disappointed Americans.

It's been weird. It's been so weird to me. And there's also... Now, I know there's a little bit of concern about this vaccine, but I also have people that have been advocating for it, which is Covaxin, which is a whole viral alternative, and that we have these alternatives. And you would think that public health would be interested in helping doctors provide informed consents to their patient.

It's been weird. It's been so weird to me. And there's also... Now, I know there's a little bit of concern about this vaccine, but I also have people that have been advocating for it, which is Covaxin, which is a whole viral alternative, and that we have these alternatives. And you would think that public health would be interested in helping doctors provide informed consents to their patient.